Tm Bioscience Hopes To Snare Large Laboratories With Automated Tag-It Test
This article was originally published in The Gray Sheet
Executive Summary
Genetic test developer Tm Bioscience is banking on the improved throughput of an automated version of its genetic Tag-It cystic fibrosis kit to attract interest from the largest U.S. commercial clinical laboratories
You may also be interested in...
FDA Clears Tm Bioscience Cystic Fibrosis Gene Test Via De Novo
FDA's de novo clearance of Tm Bioscience's Tag-It cystic fibrosis test kit paves the way for other CFTR gene mutation detection assays to be categorized as Class II
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.